Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: Variations in conventional tumor areas and in microcystic,elongated and fragmented glands

Modern Pathology

Volumn 22, Issue 5, 2009, Pages 725-733

  Stewart, Colin J R ^a,b   Crook, Maxine L ^a   Leung, Yee C ^a   Platten, Michael ^a  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Carcinoma; Endometrial; Epithelialmesenchymal transition; Immunohistochemistry; Invasion; MELF

Indexed keywords

BETA CATENIN; CELL CYCLE PROTEIN; CYCLIN D1; PROTEIN P16; REGULATOR PROTEIN;

ADULT; AGED; ANATOMICAL VARIATION; ARTICLE; CANCER CELL; CANCER INVASION; CELL NUCLEUS; CELL TRANSFER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENDOMETRIUM CARCINOMA; EPITHELIUM CELL; FEMALE; FRAGMENTATION REACTION; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH VESSEL; MESENCHYME CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BETA CATENIN; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 67349268771     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.33     Document Type: Article

References (53)

1. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005;366:491-505.
2. Sorosky JI. Endometrial cancer. Obstet Gynecol 2008;111:436-447.
3. Abal M, Planaguma J, Gil-Moreno A, et al. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histol Histopathol 2006;21:197-204.
4. Salvesen HB, Asklen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 2002;110:673-689.
5. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;29: 4783-4791.
6. Horree N, van Diest PJ, van der Groep P, et al. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol 2008;61:36-42.
7. Michalides RJAM. Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J Clin Pathol 1999;52:555-568.
8. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-737.
9. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signalling pathway. Cancer Sci 2003;94:225-229.
10. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-112.
11. Fodde R, Brabletz T. Wnt/b-catenin signalling in cancer stemness and malignant behaviour. Curr Opin Cell Biol 2007;19:150-158.
12. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007;39:305-318.
13. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-454.
14. Hugo H, Ackland ML, Blick T, et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007;213:374-383.
15. Semczuk A, Cybulski M, Tomaszewski J, et al. Clinicoprognostic significance of pRb 1 pathway alterations in uterine endometrial adenocarcinoma. Cancer Genet Cytogenet 2004;154:186-189.
16. Saegusa M, Hashimura M, Kuwata T, et al. Induction of p16INK4A mediated by b-catenin in a TCF4-independent manner: implications for alterations in p16INK4A and pRb expression during trans-differentiation of endometrial carcinoma cells. Int J Cancer 2006;119: 2294-2303.
17. Le NH, Franken P, Fodde R. Tumour-stroma interactions in colorectal cancer: converging on β-catenin activation and cancer stemness. Br J Cancer 2008;98: 1886-1893.
18. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinomas: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol 2003;22:324-333.
19. Stewart CJR, Brennan BA, Leung YC, et al. MELF pattern invasion in endometrial carcinoma: association with low-grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology (in press).
20. Stewart CJR, Little L. Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology (in press).
21. Silva EG, Deavers MT, Bodurka DC, et al. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 2006; 25:52-58.
22. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007;50:151-162.
23. Brabletz T, Hlubek F, Spaderna S, et al. Invasion and metastases in colorectal cancer: epithelial-mesenchymal Endometrial carcinoma invasion CJR Stewart et al 732 Modern Pathology (2009) 22, 725-733 transition, mesenchymal-epithelial transition, stem cells and β-catenin. Cells Tissues Organs 2005; 179:56-65.
24. Wu W, Slomovitz BM, Soliman PT, et al. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. Int J Gynecol Cancer 2006;16:1668-1672.
25. Quddus MR, Latkovich P, Castellani WJ, et al. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrial carcinoma suggests a role in endometrial carcinogenesis. Arch Pathol Lab Med 2002;126:459-463.
26. Cao QJ, Einstein MH, Anderson PS, et al. Expression of COX-2, Ki-67, cyclin D1 and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol 2002; 21:147-154.
27. Semczuk A, Miturski R, Skomra D, et al. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features. Arch Gynecol Obstet 2004;269:104-110.
28. Nikaido T, Li S-F, Shiozawa T, et al. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 1996;78: 1248-1253.
29. Ito K, Sasano H, Yoshida Y, et al. Immunohistochemical study of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma. Anticancer Res 1998;18:1661-1664.
30. Horree N, van Diest PJ, Sie-Go DMDS, et al. The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol 2007;38:1232-1238.
31. Kobayashi K, Sagae S, Nishioka Y, et al. Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res 1999;90:55-59.
32. Moreno-Bueno G, Hardisson D, Sarrio D, et al. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 2003;199:471-478.
33. Saegusa M, Hashimura M, Yoshida T, et al. b-Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001;84: 209-217.
34. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 2002;33:206-212.
35. Fukuchi T, Sakamoto M, Tsuda H, et al. b-Catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526-3528.
36. Nei H, Saito T, Yamasaki H, et al. Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Mol Carcinog 1999;25:207-218.
37. Palacios J, Catasus L, Moreno-Bueno G, et al. Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Arch 2001;438: 464-469.
38. Shih H-C, Shiozawa T, Miyamoto T, et al. Immunohistochemical expression of E-cadherin and b-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear b-catenin expression. Anticancer Res 2004;24: 3843-3850.
39. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004;22:1242-1252.
40. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-695.
41. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006;13:8-15.
42. Semczuk A, Boltze C, Marzec B, et al. p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol 2003;129:589-596.
43. Tsuda H, Yamamoto K, Inoue T, et al. The role of p16-cyclin D/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br J Cancer 2000;82:675-682.
44. Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000;6:153-159.
45. Milde-Langosch K, Riethdorf L, Bamberger A-M, et al. P16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch 1999;434:23-28.
46. Nakashima R, Fujita M, Enomoto T, et al. Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 1999;80:458-467.
47. Engelsen IB, Stefansson I, Akslen LA, et al. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol 2006;195:979-986.
48. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006;19:1091-1100.
49. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003;22:231-235.
50. Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas. Immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004;28:160-167.
51. Shiozawa T, Nikaido T, Shimizu M, et al. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 1997;80:2250-2256.
52. Jie G, Zhixiang S, Lei S, et al. Relationship between expression and methylation status of p16INK4a and the proliferative activity of different areas' tumour cells in human colorectal cancer. Int J Clin Pract 2007;61: 1523-1529.
53. Jung A, Schrauder M, Oswald U, et al. The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol 2001;159:1613-1617.